There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AN2 Therapeutics, Inc. (ANTX – Research Report) and Heron Therapeutics (HRTX – Research Report) with bullish sentiments.
AN2 Therapeutics, Inc. (ANTX)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on AN2 Therapeutics, Inc. today and set a price target of $6.00. The company’s shares closed last Wednesday at $2.27, close to its 52-week low of $2.20.
According to TipRanks.com, Buchanan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
AN2 Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $5.50, which is a 135.0% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Heron Therapeutics (HRTX)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics, with a price target of $5.00. The company’s shares closed last Wednesday at $3.00, close to its 52-week high of $3.22.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $6.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANTX:
- AN2 Therapeutics reports Q1 EPS (56c), consensus (62c)
- AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities
- AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
- AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)
- ANTX Earnings this Week: How Will it Perform?
